Abstract:Improvements in neonatal intensive care have resulted in more extremely low birthweight babies surviving who are at risk of developing chronic lung disease. The preterm lung is vulnerable as it is both structurally immature and deficient in surfactant and antioxidant defences. Mechanical ventilation and high inspired oxygen concentrations are often necessary for preterm babies to survive but they can cause pulmonary inflammation which leads to lung damage. Abnormal healing in the presence of ongoing inflammation leads to airways remodelling which can result in protracted respiratory problems in these babies. A commonly used definition for chronic lung disease is the requirement for supplemental oxygen beyond 36 weeks’ postconception.Many drugs that are commonly used for chronic lung disease have not been subjected to proper randomised controlled trials but are widely used on the basis of small studies showing short term benefits. They can be broadly divided into 2 groups. First, there are preventative drugs that are administered early to reduce oxygen toxicity and pulmonary inflammation. Secondly, there are those administered in established chronic lung disease, designed to reduce respiratory morbidity. Pulmonary inflammation in the neonate is reduced by systemic corticosteroids. Corticosteroid therapy within the first 2 weeks of life enables earlier extubation of preterm babies with subsequent reduced chronic lung disease and improved neonatal survival when given between 7 and 14 days. However, there is an increased risk of gastrointestinal haemorrhage, metabolic derangement, ventricular hypertrophy and potential effects on long term growth and brain development. Diuretics and inhaled bronchodilators improve pulmonary compliance and reduce oxygen requirements in established chronic lung disease but probably have little effect in reducing the incidence. In babies with established chronic lung disease, home oxygen therapy enables earlier discharge and prophylaxis against respiratory syncytial virus can reduce morbidity from bronchiolitis. All of the above therapies have adverse effects that need to be considered before initiating treatment.Recently, new drugs have become available which may be beneficial. These include inhaled nitric oxide for reduction of ventilation-perfusion mismatching, recombinant human superoxide dismutase for protection against oxidative stress and alpha-1 proteinase inhibitor which may reduce airways remodelling. At present these therapies are undergoing clinical trials. Exogenous surfactant is beneficial in respiratory distress syndrome and may reduce the risk of chronic lung disease but there have been no randomised controlled trials of its use in established chronic lung disease. Drugs which have been tried unsuccessfully include erythromycin, ambroxol and mast cell stabilisers.

Inhibition of the development of the bursa of Fabricius in the embryos of the common fowl by 19-nortestosterone.

Epidemiology of Respiratory Distress and the Illness Severity in Late Preterm or Term Infants: A Prospective Multi-Center Study

Neonatal pulmonology: optimizing transition and lung function in preterm infants

Considerations in the management of hypoxemic respiratory failure and persistent pulmonary hypertension in term and late preterm neonates

Hemodynamic consequences of respiratory interventions in preterm infants

Can we balance early exogenous surfactant therapy and non-invasive respiratory support to optimise outcomes in extremely preterm infants? A nuanced review of the current literature

Persistent Pulmonary Hypertension of the Newborn: Recent Advances in the Management

Response in Endothelial Cells Synthase via Endoplasmic Reticulum Stress Downregulates Endothelial Nitric Oxide HLA-B 35 Upregulates Endothelin-1 and Trojanowska and Raffaella

Cardiorespiratory Monitoring Data to Predict Respiratory Outcomes in Extremely Preterm Infants

1,25‐dihydroxy vitamin D3 and 12‐O‐tetradecanoyl phorbol‐13‐acetate synergistically induce monocytic cell differentiation: FOS and RB expression

A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease

Outpatient Respiratory Management of Infants, Children, and Adolescents with Post-Prematurity Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline

Narrative review of perinatal management of extremely preterm infants: what’s the evidence?

Pulmonary vasodilator strategies in neonates with acute hypoxemic respiratory failure and pulmonary hypertension

Nitric oxide for the treatment of preterm infants with severe RDS and pulmonary hypertension

Highly stereoselective [4+2] cycloaddition of azlactones to β,γ-unsaturated α-ketoesters catalyzed by an axially chiral guanidine base.

Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches

Current and Future Treatments for Persistent Pulmonary Hypertension in the Newborn

Bone morphogenetic protein gene therapy for the induction of spinal arthrodesis.

The respiratory consequences of preterm birth: from infancy to adulthood